Reviewer’s report

Title: Congenital emphysematous lung disease associated with a novel Filamin A mutation. Case report and literature review

Version: 1 Date: 21 Feb 2019

Reviewer: Nadia Nathan

Reviewer's report:

The manuscript has been improved a lot. It remains a few fuzzy things and some mistakes in spelling the mutations in Table 1.

- Case presentation
  line 100-102 "After stabilization…" The sentence remains unclear, is a verb missing?
  Line 122 "Genomic DNA sequencing… "The term next generation sequencing is missing: "Genomic next generation sequencing…."
  Line 130 "cystic fibrosis "ar" ?? to be deleted
  Line 141 "of the patient" is missing at the end of the sentence

- Discussion
  Line 180: the ref is missing.

- Table 1:
  The amino-acids are spelled either with 3 letters or 1 letter. Uniformize. Ex: Val / V
  FLNA has to be italized
  *and the number are missing after some fs mutations
  What is "ter"? STOP codon? If so, use *

- Legends to Figure
  Figure 2 legend is repeated twice
  Figure 3 is still unclear: explain why Tenascin staining is abnormal?
Figure 4: Use different arrows for PVNH and other abnormalities

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Unable to assess

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

Not relevant to this manuscript

Quality of written English
Please indicate the quality of language in the manuscript:

Needs some language corrections before being published

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or
has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal